Insider Transactions Reported by 32 Insiders of
LEXICON PHARMACEUTICALS, INC.
-
Symbol
-
LXRX on Nasdaq
-
Location
-
The Woodlands, TX
Quick Takeaways
- LXRX - LEXICON PHARMACEUTICALS, INC. has 32 insiders with reported activity on this page.
- Net insider value flow over the last year: +$2,722,625.
- Recent transaction rows are available for direct filing-level review.
What Changed
- Buy value: $2,722,625; sell value: $0.
- Net share flow: <span class="text-green-600">+2,058,959</span>.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Official SEC Source
Filed on Form 4
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
See Original Filing
Insiders trading volume in the past year
Insider trading buckets (0-12 months)
LEXICON PHARMACEUTICALS, INC. executives and other stock owners filed with the SEC include:
| Name |
Relationship |
Holdings Value |
Past Year Net Change |
Change % |
Valuation |
Report Date |
| International S.c.a. Artal |
Director, 10%+ Owner |
$356,792,860 |
|
|
Mixed |
10 May 2024 |
| Siren, L.L.C. |
Director, 10%+ Owner |
$92,755,045 |
|
|
Mixed |
25 Jul 2024 |
| Raymond Debbane |
Director |
$77,568,743 |
+$722,624 |
+0.94% |
Mixed |
25 Feb 2026 |
| Artal Participations S.a r.l. |
Director, 10%+ Owner |
$26,548,255 |
|
|
Mixed |
17 Feb 2026 |
| Invus Global Management, LLC |
Director, 10%+ Owner |
$25,864,432 |
+$2,000,001 |
+8.4% |
Mixed |
02 Feb 2026 |
| Invus US Partners LLC |
Director, 10%+ Owner |
$6,090,969 |
|
|
Mixed |
05 Aug 2022 |
| Lonnel Coats |
Chief Executive Officer, Director |
$3,507,748 |
|
|
Mixed |
28 Feb 2024 |
| Avicenna Life Sci Master Fund LP |
Director, 10%+ Owner |
$1,815,385 |
|
|
Mixed |
02 Feb 2026 |
| Ph.D. Michael Exton |
Chief Executive Officer, Director |
$1,450,254 |
|
|
Mixed |
28 Feb 2026 |
| Jeffrey L. Wade |
President and COO |
$1,106,796 |
|
|
Mixed |
08 Jul 2024 |
| Brian T. Crum |
SVP, General Counsel & Secr. |
$805,650 |
|
|
Mixed |
28 Feb 2026 |
| B. Kassler Taub |
SVP, Regulatory & QA |
$597,845 |
|
|
Mixed |
28 Feb 2024 |
| Craig B. Granowitz |
SVP, Chief Medical Officer |
$574,906 |
|
|
Mixed |
28 Feb 2026 |
| Wendy E. McDermott |
SVP, Human Resources |
$478,683 |
|
|
Mixed |
28 Feb 2026 |
| Scott M. Coiante |
SVP, Chief Financial Officer |
$476,949 |
|
|
Mixed |
28 Feb 2026 |
| Ph.D. Alan J. Main |
EVP, Innov & Chem Sciences |
$318,646 |
|
|
Mixed |
28 Feb 2025 |
| Brian T. Corrigan |
SVP, Regulatory & QA |
$300,602 |
|
|
Mixed |
13 Feb 2025 |
| Philippe Amouyal |
Director |
$241,880 |
|
|
Mixed |
03 Jun 2025 |
| Thomas Garner |
SVP, Chief Commercial Officer |
$239,236 |
|
|
Mixed |
08 Feb 2024 |
| Robert J. Lefkowitz MD |
Director |
$223,156 |
|
|
Mixed |
13 May 2024 |
| M.s Ph.D. Suma Gopinathan |
SVP, Discovery |
$220,694 |
|
|
Mixed |
28 Feb 2026 |
| Christopher J. Sobecki |
Director |
$200,413 |
|
|
Mixed |
03 Jun 2025 |
| Lisa M. DeFrancesco |
SVP, IR and Corp Comm |
$171,049 |
|
|
Mixed |
28 Feb 2026 |
| Sam L. Barker |
Director |
$159,916 |
|
|
Mixed |
03 Jun 2025 |
| Judith L. Swain |
Director |
$139,880 |
|
|
Mixed |
03 Jun 2025 |
| Diane E. Sullivan |
Director |
$115,215 |
|
|
Mixed |
03 Jun 2025 |
| Ph.D. Kiernan Seth |
VP, Chief Commercial Officer |
$104,343 |
|
|
Mixed |
28 Feb 2023 |
| Kristen L. Alexander |
VP, Finance and Accounting |
$77,815 |
|
|
Mixed |
28 Feb 2025 |
| Rachel Y. Martens |
SVP, Partnerships & Corp Strat |
$45,958 |
|
|
Mixed |
28 Feb 2026 |
| Alan S. Nies |
Director |
$43,234 |
|
|
Mixed |
21 May 2023 |
| Frank Palantoni |
Director |
$42,482 |
|
|
Mixed |
21 May 2023 |
| Ivan H. Cheung |
Director |
|
|
|
Mixed |
03 Jun 2025 |
Recent Insider Transactions by Companies or Individuals for LEXICON PHARMACEUTICALS, INC.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider |
Symbol |
Class |
Transaction |
% |
Value $ |
* Price $ |
Shares |
Shares Owned |
Date |
Ownership |
| Wendy E. McDermott |
LXRX |
Common Stock |
Tax liability |
-19.7% |
|
|
-68,107 |
277,945 |
28 Feb 2026 |
Direct |
| Wendy E. McDermott |
LXRX |
Common Stock |
Options Exercise |
184.5% |
|
|
224,406 |
346,052 |
28 Feb 2026 |
Direct |
| Wendy E. McDermott |
LXRX |
Restricted Stock Units |
Options Exercise |
-100% |
|
|
-224,406 |
0 |
28 Feb 2026 |
Direct |
| Rachel Y. Martens |
LXRX |
Common Stock |
Tax liability |
-53.4% |
|
|
-35,826 |
31,264 |
28 Feb 2026 |
Direct |
| Rachel Y. Martens |
LXRX |
Common Stock |
Options Exercise |
|
|
|
67,090 |
67,090 |
28 Feb 2026 |
Direct |
| Rachel Y. Martens |
LXRX |
Restricted Stock Units |
Options Exercise |
-33.3% |
|
|
-67,090 |
134,180 |
28 Feb 2026 |
Direct |
| Craig B. Granowitz |
LXRX |
Common Stock |
Tax liability |
-25.2% |
|
|
-109,098 |
323,430 |
28 Feb 2026 |
Direct |
| Craig B. Granowitz |
LXRX |
Common Stock |
Options Exercise |
259.7% |
|
|
312,276 |
432,528 |
28 Feb 2026 |
Direct |
| Craig B. Granowitz |
LXRX |
Restricted Stock Units |
Options Exercise |
-100% |
|
|
-312,276 |
0 |
28 Feb 2026 |
Direct |
| M.s Ph.D. Suma Gopinathan |
LXRX |
Common Stock |
Tax liability |
-14% |
|
|
-24,338 |
150,132 |
28 Feb 2026 |
Direct |
| M.s Ph.D. Suma Gopinathan |
LXRX |
Common Stock |
Options Exercise |
134.1% |
|
|
99,950 |
174,470 |
28 Feb 2026 |
Direct |
| M.s Ph.D. Suma Gopinathan |
LXRX |
Restricted Stock Units |
Options Exercise |
-100% |
|
|
-99,950 |
0 |
28 Feb 2026 |
Direct |
| Lisa M. DeFrancesco |
LXRX |
Common Stock |
Tax liability |
-44.3% |
|
|
-74,572 |
93,869 |
28 Feb 2026 |
Direct |
| Lisa M. DeFrancesco |
LXRX |
Common Stock |
Options Exercise |
981.3% |
|
|
152,864 |
168,441 |
28 Feb 2026 |
Direct |
| Lisa M. DeFrancesco |
LXRX |
Restricted Stock Units |
Options Exercise |
-86.1% |
|
|
-152,864 |
24,673 |
28 Feb 2026 |
Direct |
| Brian T. Crum |
LXRX |
Common Stock |
Tax liability |
-19.7% |
|
|
-105,019 |
428,802 |
28 Feb 2026 |
Direct |
| Brian T. Crum |
LXRX |
Common Stock |
Options Exercise |
104.7% |
|
|
273,006 |
533,821 |
28 Feb 2026 |
Direct |
| Brian T. Crum |
LXRX |
Restricted Stock Units |
Options Exercise |
-100% |
|
|
-273,006 |
0 |
28 Feb 2026 |
Direct |
| Scott M. Coiante |
LXRX |
Common Stock |
Tax liability |
-34.2% |
|
|
-54,881 |
105,356 |
28 Feb 2026 |
Direct |
| Scott M. Coiante |
LXRX |
Common Stock |
Options Exercise |
|
|
|
160,237 |
160,237 |
28 Feb 2026 |
Direct |
| Scott M. Coiante |
LXRX |
Restricted Stock Units |
Options Exercise |
-33.3% |
|
|
-160,237 |
320,473 |
28 Feb 2026 |
Direct |
| Ph.D. Michael Exton |
LXRX |
Common Stock |
Tax liability |
-40.7% |
|
|
-204,831 |
298,432 |
28 Feb 2026 |
Direct |
| Ph.D. Michael Exton |
LXRX |
Common Stock |
Options Exercise |
|
|
|
503,263 |
503,263 |
28 Feb 2026 |
Direct |
| Ph.D. Michael Exton |
LXRX |
Restricted Stock Units |
Options Exercise |
-33.3% |
|
|
-503,263 |
1,006,527 |
28 Feb 2026 |
Direct |
| Raymond Debbane |
LXRX |
Common Stock |
Purchase |
0.11% |
$2,980 |
$1.49 |
2,000 |
1,906,186 |
25 Feb 2026 |
Direct |
| Raymond Debbane |
LXRX |
Common Stock |
Purchase |
5.54% |
$147,000 |
$1.47 |
100,000 |
1,904,186 |
23 Feb 2026 |
Direct |
| Raymond Debbane |
LXRX |
Common Stock |
Purchase |
5.87% |
$147,790 |
$1.48 |
100,000 |
1,804,186 |
20 Feb 2026 |
Direct |
| Raymond Debbane |
LXRX |
Common Stock |
Purchase |
3.02% |
$71,965 |
$1.44 |
50,000 |
1,704,186 |
19 Feb 2026 |
Direct |
| Raymond Debbane |
LXRX |
Common Stock |
Purchase |
8.79% |
$176,468 |
$1.32 |
133,688 |
1,654,186 |
18 Feb 2026 |
Direct |
| Artal Participations S.a r.l. |
LXRX |
Series B Convertible Preferred Stock |
Award |
11.2% |
|
|
41,290 |
408,435 |
17 Feb 2026 |
See Footnotes |
| Raymond Debbane |
LXRX |
Common Stock |
Purchase |
5.32% |
$100,544 |
$1.31 |
76,857 |
1,520,498 |
17 Feb 2026 |
Direct |
| Raymond Debbane |
LXRX |
Common Stock |
Purchase |
4.18% |
$75,877 |
$1.31 |
57,952 |
1,443,641 |
13 Feb 2026 |
Direct |
| Wendy E. McDermott |
LXRX |
Stock Option (Right to Buy) |
Award |
|
|
|
375,300 |
375,300 |
12 Feb 2026 |
Direct |
| Wendy E. McDermott |
LXRX |
Restricted Stock Units |
Award |
|
|
|
250,200 |
250,200 |
12 Feb 2026 |
Direct |
| Rachel Y. Martens |
LXRX |
Stock Option (Right to Buy) |
Award |
|
|
|
290,620 |
290,620 |
12 Feb 2026 |
Direct |
| Rachel Y. Martens |
LXRX |
Restricted Stock Units |
Award |
|
|
|
193,740 |
193,740 |
12 Feb 2026 |
Direct |
| Craig B. Granowitz |
LXRX |
Stock Option (Right to Buy) |
Award |
|
|
|
519,920 |
519,920 |
12 Feb 2026 |
Direct |
| Craig B. Granowitz |
LXRX |
Restricted Stock Units |
Award |
|
|
|
346,610 |
346,610 |
12 Feb 2026 |
Direct |
| M.s Ph.D. Suma Gopinathan |
LXRX |
Stock Option (Right to Buy) |
Award |
|
|
|
357,680 |
357,680 |
12 Feb 2026 |
Direct |
| M.s Ph.D. Suma Gopinathan |
LXRX |
Restricted Stock Units |
Award |
|
|
|
238,450 |
238,450 |
12 Feb 2026 |
Direct |
| Lisa M. DeFrancesco |
LXRX |
Stock Option (Right to Buy) |
Award |
|
|
|
386,300 |
386,300 |
12 Feb 2026 |
Direct |
| Lisa M. DeFrancesco |
LXRX |
Restricted Stock Units |
Award |
|
|
|
257,530 |
257,530 |
12 Feb 2026 |
Direct |
| Brian T. Crum |
LXRX |
Stock Option (Right to Buy) |
Award |
|
|
|
449,560 |
449,560 |
12 Feb 2026 |
Direct |
| Brian T. Crum |
LXRX |
Restricted Stock Units |
Award |
|
|
|
299,710 |
299,710 |
12 Feb 2026 |
Direct |
| Scott M. Coiante |
LXRX |
Stock Option (Right to Buy) |
Award |
|
|
|
409,020 |
409,020 |
12 Feb 2026 |
Direct |
| Scott M. Coiante |
LXRX |
Restricted Stock Units |
Award |
|
|
|
272,680 |
272,680 |
12 Feb 2026 |
Direct |
| Ph.D. Michael Exton |
LXRX |
Stock Option (Right to Buy) |
Award |
|
|
|
1,293,670 |
1,293,670 |
12 Feb 2026 |
Direct |
| Ph.D. Michael Exton |
LXRX |
Restricted Stock Units |
Award |
|
|
|
862,440 |
862,440 |
12 Feb 2026 |
Direct |
| Invus Global Management, LLC |
LXRX |
Series B Convertible Preferred Stock |
Award |
|
|
|
367,145 |
367,145 |
02 Feb 2026 |
See Footnotes |
| Invus Global Management, LLC |
LXRX |
Common Stock |
Purchase |
|
$2,000,001 |
$1.30 |
1,538,462 |
1,538,462 |
02 Feb 2026 |
See Footnotes |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.